HIV/AIDS Vaccine Facility (C06)

The summary for the HIV/AIDS Vaccine Facility (C06) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
HIV/AIDS Vaccine Facility (C06): Development and testing of AIDS vaccines are high priorities for NIH-supported research (NOT-OD-15-137). This Funding Opportunity Announcement (FOA) invites applications from qualified academic institutions to apply for support to upgrade existing functioning space to Current Good Manufacturing Practice (CGMP) standards for production of next generation candidates for HIV/AIDS vaccines, with the goal of creating sufficient quantities of immunogens to conduct Phase I clinical trials. The applicants should: a) demonstrate the highest level of expertise in HIV/AIDS biology and have experience in development and testing of concepts for AIDS vaccines; b) have vaccine candidates that have been produced in pre-clinical lots and tested for immunogenicity in appropriate animal models; c) have vaccine candidates that can be scaled up from pre-clinical lots to CGMP standards for Phase I clinical trials; d) have the capability and analytics expertise to conduct process development, and scale-up production of pharmaceutical quality compounds to clinical trials-levels, and e) have the ability to implement Phase I clinical trials. In parallel, the applicants should demonstrate the highest level of skill and competency in all technical aspect of the design, construction, and commissioning of the facility, to ensure that relevant Federal and Industry standards are met for production of pharmaceutical grade compounds.
Federal Grant Title: HIV/AIDS Vaccine Facility (C06)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-16-290
Type of Funding: Grant
CFDA Numbers: 323118, 323119
CFDA Descriptions: Construction Support
Current Application Deadline: Aug 1, 2016
Original Application Deadline: Aug 1, 2016
Posted Date: May 25, 2016
Creation Date: May 26, 2016
Archive Date: Sep 1, 2016
Total Program Funding: $4,900,000
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards: 1
Cost Sharing or Matching: Yes
Applicants Eligible for this Grant
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-16-290.html
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405